Novartis, GSK deal puts the spotlight on a narrowing R&D focus
John Carroll
The big trend in Big Pharma R&D has been to cut back significantly in key areas where they felt they faced extraordinarily high risks–a particular problem in ...
Docs that just say no to drug samples slash brand prescribing big-time, study finds
Tracy Staton
A new JAMA Dermatology study shows a huge difference in brand-name scripts written by physicians who turn down drug samples–a 62-percentage-point difference, ...
Nasdaq volatility delays IPO, Almirall pulls drug over price, Topotarget to merge as PDUFA nears
Nick Paul Taylor
Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions ...
Second drug spending report predicts double-digit increases coming
Eric Palmer
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes ...
EU takes up testosterone drug review on cardio worries
Carly Helfand
The FDA has been reviewing testosterone drugs since January of this year on concerns over their cardiovascular safety. Now, its across-the-pond counterpart is following ...
Vivus needs more than boardroom shuffling to keep up with Arena’s Belviq
Carly Helfand
One pre-First Manhattan Co.-settlement Vivus director standing for re-election at the company's annual meeting, that is. The Mountain View, CA-based drugmaker announced ...
National Cancer Institute investigating trial outliers to resurrect ‘failed’ drugs
Emily Mullin
After sifting through 10 years' worth of clinical trial data, NCI's Cancer Diagnosis Program says the program has identified about 100 "exceptional responders": ...
Biotech stock tumble stumps analysts
Carly Helfand
Nobody quite knows why the Nasdaq biotech index sank another 5.6% on Thursday. Analysts do know that the drop came the day after the index jumped 4.1%, also inexplicably, ...
GSK buys full control of consumer unit in Indonesia
Eric Palmer
Indonesia is one of the rapidly growing markets that drugmakers are trying to tap to boost sales, and GlaxoSmithKline is upping its bet. The U.K.-based drugmaker said today ...
Sage snags $38M from A-list VCs to bankroll its seizure drugs
Damian Garde
Cambridge, MA's Sage Therapeutics has hauled in a $ 38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio ...
Geron shares blasted as FDA slams the brakes on imetelstat studies
John Carroll
Geron is back in the tank. The biotech's shares were in meltdown mode Wednesday morning, plunging about 60% in premarket trading after the company announced that the ...